

S3 Table. Neoadjuvant TCHP chemotherapy response

	No. (%)
	(n=447)
Pathologic stage	
Pathologic CR	286 (64.0)
YpT0N0	211 (47.2)
YpTisN0	75 (16.8)
Non-pathologic CR	161 (36.0)
Recurrence	33
RCB class	
RCB 0	290 (64.9)
RCB 1	54 (12.1)
RCB 2	64 (14.3)
RCB 3	8 (1.8)
Unknown	31 (6.9)
Death	2

CR, complete response; RCB, residual cancer burden;
TCHP, docetaxel/carboplatin/trastuzumab/pertuzumab.